Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder

Journal of Clinical Pathology

Volumn 49, Issue 5, 1996, Pages 395-399

  Shiina, H ^a   Igawa, M ^a   Urakami, S ^a   Honda, S ^a   Shirakawa, H ^a   Ishibe, T ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Bcl 2; Bladder cancer; DNA content; Immunohistochemistry; p53; PCNA

Indexed keywords

CYCLINE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

EID: 0030043995     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.5.395     Document Type: Article

References (29)

1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondorial membrane protein that blocks programmed cell death. Nature 1990; 348:334-6.
2. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
3. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214-18.
4. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994;145:1036-40.
5. Fontanini G, Vignati S, Bigni D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995;71:1003-7.
6. van den Oord JJ, Vandeghinste N, de Ley M, de Wolf Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145:294-300.
7. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
8. Bhargava V, Kell DL, van den Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994;145:535-40.
9. Pilotti S, Collini O, Rilke F, Cattoretti G, Bo RD, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172:337-42.
10. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
11. Levine AL, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
12. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57: 1083-93.
13. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-16.
14. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991;253:49-53.
15. Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990;96:121-9.
16. Tan CK, Castillo C, So AG, Downey KM. An auxiliary protein for DNA polymerase delta from fetal calf thymus. J Biol Chem 1986;261:1231-6.
17. Auffermann W, Urquardt M, Rubben H, Wohltmann D, Böcking A. DNA grading of urothelial carcinoma of the bladder. Anticancer Res 1986;6:27-32.
18. Granzen B, Auffermann W. Algorithm for a DNA cytophotometric diagnosis and grading of malignancy. Anal Quant Cytol 1984;6:1-8.
19. UICC. TNM classification of malignant tumours. 3rd edn. Geneva: UICC, 1978.
20. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. In: International histological classification of tumours. No. 10. Geneva: World Health Organization, 1973.
21. Bacus JW, Grade LJ. Optical microscope system for standardized cell measurements and analyses. Appl Optics 1987; 26:3280-93.
22. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathologieal correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994;424:47-51.
23. Levine AJ. The p53 tumor suppressor gene. N Engl J Med 1992;326:1350-2.
24. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993;53:4776-80.
25. Lipponen PK. Expression of nuclear oncoprotein p53 in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-70.
26. Lipponen PK, Nordling S, Eskelinen MJ, Janhiainen KJ, Terho R, Harju E. Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional cell bladder cancer. Int J Cancer 1993;53:42-7.
27. Lipponen PK, Eskelinen MJ, Janhiainen K, Harju E, Terho R, Haapasalo H. Independent clinical, histological and quantitative prognostic factors in transitional cell bladder tumours, with special reference to mitotic frequency. Int J Cancer 1992;51:396-403.
28. Hemstreet GP 3rd, Rollins S, Jones P, Rao JY, Hurst RE, Bonner RB, et al. Identification of a high risk subgroup of grade 1 transitional cell carcinoma using image analysis based deoxyribonucleic acid ploidy analysis of tumor tissue. J Unol 1991;146:1525-9.
29. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173:333-9.